Clinical Experience with Generic Rasagiline (Ralago®) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study
Open Access
- 1 January 2019
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in Advances in Parkinson's Disease
- Vol. 08 (02), 18-34
- https://doi.org/10.4236/apd.2019.82003
Abstract
Background: Antiparkinsonian pharmacotherapy represents one of the most important expenses related to Parkinson’s disease. The application of generic drugs may help to reduce the economic burden of the disease; however, efficacy and safety of these products have been less studied. Objective: To investigate the efficacy and safety of generic rasagiline (Ralago®) from a clinical perspective. Methods: The Clinical Global Impression of Severity scale was used to rate the most important motor and non-motor symptoms at baseline and 12 weeks after the initiation of Ralago®. Patients also identified symptoms which were the main sources of their disability and distress in everyday life. Results: A total of 499 patients were enrolled (231 females, mean age: 73.2 ± 9.1 years, mean duration of disease: 3.6 ± 3.7 years). Of them, 486 patients completed the study protocol. Both motor and non-motor symptoms showed improvement during 12-week Ralago® treatment. Adverse events were rare, and the majority of them were not considered as serious. Conclusions: The generic rasagiline (Ralago®) is an effective and safe generic product.Keywords
This publication has 29 references indexed in Scilit:
- Quality of Reporting of Bioequivalence Trials Comparing Generic to Brand Name Drugs: A Methodological Systematic ReviewPLOS ONE, 2011
- Late (Complicated) Parkinson's DiseasePublished by Wiley ,2010
- Costs of Parkinson’s Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort StudyNeurodegenerative Diseases, 2010
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseThe New England Journal of Medicine, 2009
- Global versus factor‐related impression of severity in Parkinson's disease: A new clinimetric index (CISI‐PD)Movement Disorders, 2006
- High doses of pergolide improve clinical global impression in advanced Parkinson's disease—A preliminary open label studyArchives of Gerontology and Geriatrics, 2005
- Cost of Illness and its Predictors for Parkinson??s Disease in GermanyPharmacoEconomics, 2005
- Neuroprotective effect of rasagiline in a rodent model of Parkinson's diseaseExperimental Neurology, 2004
- Health related quality of life in Parkinson's disease: a prospective longitudinal studyJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Pharmacokinetic comparison of sinemet and atamet (Generic carbidopa/levodopa): A single‐dose studyMovement Disorders, 1996